Palatine Capital Partners

The company develops precision oncology therapeutics that target DNA Damage Repair (DDR) pathways to enhance anti-tumor immunity. By discovering small molecule modulators, it provides patients with new treatment options for cancer and related diseases.

Traction 6/10

HQ unknown

Founded 200726700+ followers

Biotechnology

Updated 7 months ago

Funding

Raised to date

$9.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

1 founder

Greg Laird

Managing Member

Product

Features

The company develops precision oncology therapeutics that target DNA Damage Repair (DDR) pathways to enhance anti-tumor immunity. By discovering small molecule modulators, it provides patients with new treatment options for cancer and related diseases.